<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02341144</url>
  </required_header>
  <id_info>
    <org_study_id>41103</org_study_id>
    <nct_id>NCT02341144</nct_id>
  </id_info>
  <brief_title>Percutaneous Rectus Sheath Block Versus Intra-operative Rectus Sheath Block for Pediatric Umbilical Hernia Repair</brief_title>
  <official_title>Percutaneous Rectus Sheath Block Versus Intra-operative Rectus Sheath Block for Pediatric Umbilical Hernia Repair: A Prospective, Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins All Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins All Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, double-blinded, randomized controlled study comparing the efficacy of
      pre-incisional percutaneous rectus sheath block to intra-operative rectus sheath block under
      direct visualization prior to closure of the incision for providing post-operative analgesia
      following umbilical hernia repair in children. The current management for reducible umbilical
      hernias is umbilical hernia repair under general anesthesia as an outpatient procedure.

      Patients aged 3-18 years old with a diagnosis of umbilical hernia will be screened for study
      inclusion. Eligible patients and their parents/guardians will be approached and, if
      agreeable, consented for the study pre-operatively. Patients will be randomized to receive
      either pre-incisional percutaneous rectus sheath block by the anesthesiologist or
      intra-operative rectus sheath block under direct visualization prior to closure of the skin
      incision by the surgeon. The patient, patient guardians, select research team members, and
      post-anesthesia care unit (PACU) staff will be blinded to the method of analgesic
      administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Regional anesthesia has been increasingly utilized for providing post-operative analgesia for
      a number of surgical procedures in children. Rectus sheath block and local anesthetic
      infiltration of the surgical site are two common modes for providing post-operative analgesia
      following umbilical hernia repair. Studies comparing the two modes have shown
      ultrasound-guided rectus sheath block to improve immediate pain scores and reduce use of
      post-operative analgesia in pediatric patients undergoing umbilical hernia repair. However,
      these studies have compared pre-incisional ultrasound-guided rectus sheath block to
      post-operative local anesthetic infiltration as a subcutaneous and/or intradermal injection.

      The purpose of the investigators' study is to compare the efficacy of pre-incisional
      percutaneous rectus sheath block to intra-operative rectus sheath block under direct
      visualization prior to closure of the skin for providing post-operative analgesia following
      umbilical hernia repair in children.

      The investigators propose a prospective study where pediatric patients who are undergoing
      elective umbilical hernia repair will be randomized pre-operatively to receive either
      pre-incisional, ultrasound guided percutaneous rectus sheath block or intra-operative rectus
      sheath block under direct visualization prior to closure of the skin. The primary outcome is
      the post-operative pain rating based on the Wong-Baker Faces Pain Rating Scale (WBFPRS)
      following umbilical hernia repair. Additional outcomes measured will include: operative
      times, the use of intravenous/oral opioid and/or non-opioid medication in the post-operative
      period, duration of analgesia following surgery based on time to first rescue analgesic,
      intra-operative hemodynamic changes, post-operative hemodynamic changes, incidence of
      side-effects, and complications. Patients/patient guardians will receive a sheet to document
      post-operative WBFPRS scores, oral opioid and non-opioid medication administration once
      discharged to home for a total of 5 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">April 1, 2016</completion_date>
  <primary_completion_date type="Actual">March 1, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post Operative Pain Rating</measure>
    <time_frame>from entry in post-anesthesia care unit (PACU) until discharge, estimated 1-2 hours</time_frame>
    <description>Using the Wong-Baker FACES Pain Rating Scale (WBFPRS)- pain scores range from zero (no pain) to ten (worst pain) and the average score was reported</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to First Narcotic</measure>
    <time_frame>from entry in post-anesthesia care unit (PACU) to first narcotic</time_frame>
    <description>duration until patient received first dose of narcotic in PACU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Score of Zero</measure>
    <time_frame>from entry in the post-anesthesia care unit (PACU) until discharge, estimated 1-2 hours</time_frame>
    <description>proportion who reported a score of zero throughout their PACU stay using the Wong-Baker (WB) scale with zero being &quot;no pain&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PACU Morphine Equivalents</measure>
    <time_frame>from entry in post-anesthesia care unit (PACU) until discharge, estimated 1-2 hours</time_frame>
    <description>morphine equivalents received in PACU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PACU Length of Stay (LOS)</measure>
    <time_frame>from entry in post-anesthesia care unit (PACU) until discharge, estimated 1-2 hours</time_frame>
    <description>duration of time spent in the post-anesthesia care unit (PACU) from arrival to discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Pre-op percutaneous rectus sheath block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ultrasound-guided, percutaneous rectus sheath block with ropivacaine by a qualified anesthesiologist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intra-operative rectus sheath block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rectus sheath block with ropivacaine under direct visualization by the attending surgeon</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pre-op percutaneous rectus sheath block</intervention_name>
    <description>After induction of anesthesia, the attending anesthesiologist will use a portable ultrasound probe to locate the rectus sheath. A 22 gauge needle will be used to inject a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally). The analgesic will be injected percutaneously using ultrasound guidance between the rectus abdominis muscle and the posterior rectus sheath at the lateral border bilaterally.</description>
    <arm_group_label>Pre-op percutaneous rectus sheath block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intra-operative rectus sheath block</intervention_name>
    <description>After the completion of the umbilical hernia repair, after fascial closure, but prior to skin closure, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10c, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon.</description>
    <arm_group_label>Intra-operative rectus sheath block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <arm_group_label>Pre-op percutaneous rectus sheath block</arm_group_label>
    <arm_group_label>Intra-operative rectus sheath block</arm_group_label>
    <other_name>Naropin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 3-18 years undergoing elective umbilical hernia repair

        Exclusion Criteria:

          -  Strangulated or incarcerated umbilical hernia (non-elective)

          -  Allergy to bupivacaine/ropivicaine

          -  Concurrent surgical procedures

          -  Developmental delay or neurologic diagnosis that would interfere with post-operative
             pain score assessment

          -  Chronic pain medication use

          -  Chronic pain disorder or complex regional pain syndrome

          -  Anesthesiologist classification of III or greater.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole M Chandler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins All Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2014</study_first_submitted>
  <study_first_submitted_qc>January 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2015</study_first_posted>
  <results_first_submitted>March 2, 2017</results_first_submitted>
  <results_first_submitted_qc>April 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 16, 2017</results_first_posted>
  <last_update_submitted>April 13, 2017</last_update_submitted>
  <last_update_submitted_qc>April 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins All Children's Hospital</investigator_affiliation>
    <investigator_full_name>Nicole Chandler</investigator_full_name>
    <investigator_title>Assistant Professor of Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Hernia, Umbilical</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pre-op Percutaneous Rectus Sheath Block</title>
          <description>ultrasound-guided, percutaneous rectus sheath block by a qualified anesthesiologist
Pre-op percutaneous rectus sheath block: After induction of anesthesia, the attending anesthesiologist will use a portable ultrasound probe to locate the rectus sheath. A 22 gauge needle will be used to inject a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally). The analgesic will be injected percutaneously using ultrasound guidance between the rectus abdominis muscle and the posterior rectus sheath at the lateral border bilaterally.
Ropivacaine</description>
        </group>
        <group group_id="P2">
          <title>Intra-operative Rectus Sheath Block</title>
          <description>rectus sheath block under direct visualization by the attending surgeon
Intra-operative rectus sheath block: After the completion of the umbilical hernia repair, after fascial closure, but prior to skin closure, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10c, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon.
Ropivacaine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pre-op Percutaneous Rectus Sheath Block</title>
          <description>ultrasound-guided, percutaneous rectus sheath block by a qualified anesthesiologist
Pre-op percutaneous rectus sheath block: After induction of anesthesia, the attending anesthesiologist will use a portable ultrasound probe to locate the rectus sheath. A 22 gauge needle will be used to inject a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally). The analgesic will be injected percutaneously using ultrasound guidance between the rectus abdominis muscle and the posterior rectus sheath at the lateral border bilaterally.
Ropivacaine</description>
        </group>
        <group group_id="B2">
          <title>Intra-operative Rectus Sheath Block</title>
          <description>rectus sheath block under direct visualization by the attending surgeon
Intra-operative rectus sheath block: After the completion of the umbilical hernia repair, after fascial closure, but prior to skin closure, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10c, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon.
Ropivacaine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.2" lower_limit="3.2" upper_limit="15.4"/>
                    <measurement group_id="B2" value="6.2" lower_limit="4.1" upper_limit="17.2"/>
                    <measurement group_id="B3" value="6.2" lower_limit="3.2" upper_limit="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (BMI) percentile</title>
          <description>body mass index (BMI) percentile: weight (kg) divided by height (m) relative to other children in the US of the same age and sex</description>
          <units>percentile</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="3" upper_limit="99"/>
                    <measurement group_id="B2" value="77" lower_limit="5" upper_limit="98"/>
                    <measurement group_id="B3" value="61.2" lower_limit="3" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post Operative Pain Rating</title>
        <description>Using the Wong-Baker FACES Pain Rating Scale (WBFPRS)- pain scores range from zero (no pain) to ten (worst pain) and the average score was reported</description>
        <time_frame>from entry in post-anesthesia care unit (PACU) until discharge, estimated 1-2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-op Percutaneous Rectus Sheath Block</title>
            <description>ultrasound-guided, percutaneous rectus sheath block by a qualified anesthesiologist
Pre-op percutaneous rectus sheath block: After induction of anesthesia, the attending anesthesiologist will use a portable ultrasound probe to locate the rectus sheath. A 22 gauge needle will be used to inject a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally). The analgesic will be injected percutaneously using ultrasound guidance between the rectus abdominis muscle and the posterior rectus sheath at the lateral border bilaterally.
Ropivacaine</description>
          </group>
          <group group_id="O2">
            <title>Intra-operative Rectus Sheath Block</title>
            <description>rectus sheath block under direct visualization by the attending surgeon
Intra-operative rectus sheath block: After the completion of the umbilical hernia repair, after fascial closure, but prior to skin closure, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10c, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon.
Ropivacaine</description>
          </group>
        </group_list>
        <measure>
          <title>Post Operative Pain Rating</title>
          <description>Using the Wong-Baker FACES Pain Rating Scale (WBFPRS)- pain scores range from zero (no pain) to ten (worst pain) and the average score was reported</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0" upper_limit="6.7"/>
                    <measurement group_id="O2" value="3.3" lower_limit="0" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Narcotic</title>
        <description>duration until patient received first dose of narcotic in PACU</description>
        <time_frame>from entry in post-anesthesia care unit (PACU) to first narcotic</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-op Percutaneous Rectus Sheath Block</title>
            <description>ultrasound-guided, percutaneous rectus sheath block by a qualified anesthesiologist
Pre-op percutaneous rectus sheath block: After induction of anesthesia, the attending anesthesiologist will use a portable ultrasound probe to locate the rectus sheath. A 22 gauge needle will be used to inject a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally). The analgesic will be injected percutaneously using ultrasound guidance between the rectus abdominis muscle and the posterior rectus sheath at the lateral border bilaterally.
Ropivacaine</description>
          </group>
          <group group_id="O2">
            <title>Intra-operative Rectus Sheath Block</title>
            <description>rectus sheath block under direct visualization by the attending surgeon
Intra-operative rectus sheath block: After the completion of the umbilical hernia repair, after fascial closure, but prior to skin closure, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10c, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon.
Ropivacaine</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Narcotic</title>
          <description>duration until patient received first dose of narcotic in PACU</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="4" upper_limit="54"/>
                    <measurement group_id="O2" value="22" lower_limit="2" upper_limit="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Score of Zero</title>
        <description>proportion who reported a score of zero throughout their PACU stay using the Wong-Baker (WB) scale with zero being &quot;no pain&quot;</description>
        <time_frame>from entry in the post-anesthesia care unit (PACU) until discharge, estimated 1-2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-op Percutaneous Rectus Sheath Block</title>
            <description>ultrasound-guided, percutaneous rectus sheath block by a qualified anesthesiologist
Pre-op percutaneous rectus sheath block: After induction of anesthesia, the attending anesthesiologist will use a portable ultrasound probe to locate the rectus sheath. A 22 gauge needle will be used to inject a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally). The analgesic will be injected percutaneously using ultrasound guidance between the rectus abdominis muscle and the posterior rectus sheath at the lateral border bilaterally.
Ropivacaine</description>
          </group>
          <group group_id="O2">
            <title>Intra-operative Rectus Sheath Block</title>
            <description>rectus sheath block under direct visualization by the attending surgeon
Intra-operative rectus sheath block: After the completion of the umbilical hernia repair, after fascial closure, but prior to skin closure, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10c, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon.
Ropivacaine</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score of Zero</title>
          <description>proportion who reported a score of zero throughout their PACU stay using the Wong-Baker (WB) scale with zero being &quot;no pain&quot;</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.39</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PACU Morphine Equivalents</title>
        <description>morphine equivalents received in PACU</description>
        <time_frame>from entry in post-anesthesia care unit (PACU) until discharge, estimated 1-2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-op Percutaneous Rectus Sheath Block</title>
            <description>ultrasound-guided, percutaneous rectus sheath block by a qualified anesthesiologist
Pre-op percutaneous rectus sheath block: After induction of anesthesia, the attending anesthesiologist will use a portable ultrasound probe to locate the rectus sheath. A 22 gauge needle will be used to inject a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally). The analgesic will be injected percutaneously using ultrasound guidance between the rectus abdominis muscle and the posterior rectus sheath at the lateral border bilaterally.
Ropivacaine</description>
          </group>
          <group group_id="O2">
            <title>Intra-operative Rectus Sheath Block</title>
            <description>rectus sheath block under direct visualization by the attending surgeon
Intra-operative rectus sheath block: After the completion of the umbilical hernia repair, after fascial closure, but prior to skin closure, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10c, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon.
Ropivacaine</description>
          </group>
        </group_list>
        <measure>
          <title>PACU Morphine Equivalents</title>
          <description>morphine equivalents received in PACU</description>
          <units>mg/kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="0" upper_limit="0.24"/>
                    <measurement group_id="O2" value="0.09" lower_limit="0" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PACU Length of Stay (LOS)</title>
        <description>duration of time spent in the post-anesthesia care unit (PACU) from arrival to discharge</description>
        <time_frame>from entry in post-anesthesia care unit (PACU) until discharge, estimated 1-2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-op Percutaneous Rectus Sheath Block</title>
            <description>ultrasound-guided, percutaneous rectus sheath block by a qualified anesthesiologist
Pre-op percutaneous rectus sheath block: After induction of anesthesia, the attending anesthesiologist will use a portable ultrasound probe to locate the rectus sheath. A 22 gauge needle will be used to inject a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally). The analgesic will be injected percutaneously using ultrasound guidance between the rectus abdominis muscle and the posterior rectus sheath at the lateral border bilaterally.
Ropivacaine</description>
          </group>
          <group group_id="O2">
            <title>Intra-operative Rectus Sheath Block</title>
            <description>rectus sheath block under direct visualization by the attending surgeon
Intra-operative rectus sheath block: After the completion of the umbilical hernia repair, after fascial closure, but prior to skin closure, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10c, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon.
Ropivacaine</description>
          </group>
        </group_list>
        <measure>
          <title>PACU Length of Stay (LOS)</title>
          <description>duration of time spent in the post-anesthesia care unit (PACU) from arrival to discharge</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="56" upper_limit="159"/>
                    <measurement group_id="O2" value="80" lower_limit="49" upper_limit="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.44</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days postoperatively</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pre-op Percutaneous Rectus Sheath Block</title>
          <description>ultrasound-guided, percutaneous rectus sheath block by a qualified anesthesiologist
Pre-op percutaneous rectus sheath block: After induction of anesthesia, the attending anesthesiologist will use a portable ultrasound probe to locate the rectus sheath. A 22 gauge needle will be used to inject a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally). The analgesic will be injected percutaneously using ultrasound guidance between the rectus abdominis muscle and the posterior rectus sheath at the lateral border bilaterally.
Ropivacaine</description>
        </group>
        <group group_id="E2">
          <title>Intra-operative Rectus Sheath Block</title>
          <description>rectus sheath block under direct visualization by the attending surgeon
Intra-operative rectus sheath block: After the completion of the umbilical hernia repair, after fascial closure, but prior to skin closure, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10c, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon.
Ropivacaine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nicole Chandler</name_or_title>
      <organization>Johns Hopkins All Children's Hospital</organization>
      <phone>7277674170 ext 727</phone>
      <email>nicole.chandler@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

